scholarly journals Mitochondrial complex III Qi-site inhibitor resistance mutations found in laboratory selected mutants and field isolates

2018 ◽  
Vol 75 (8) ◽  
pp. 2107-2114 ◽  
Author(s):  
Pierre Mounkoro ◽  
Thomas Michel ◽  
Rafik Benhachemi ◽  
Georgiana Surpateanu ◽  
Bogdan I Iorga ◽  
...  
Keyword(s):  
Complex Iii ◽  
Mitochondrial Complex ◽  
Resistance Mutations ◽  
Field Isolates ◽  
Inhibitor Resistance

scholarly journals No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments

2021 ◽  
Author(s):  
Basma Abdi ◽  
Mouna Chebbi ◽  
Marc Wirden ◽  
Elisa Teyssou ◽  
Sophie Sayon ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Routine Care ◽  
Biological Data ◽  
Recombinant Form ◽  
Hiv Integrase ◽  
Resistance Mutations ◽  
Clinical Routine ◽  
Inhibitor Resistance ◽  
Hiv 1

Abstract Background Little is known about HIV-1 integrase inhibitor resistance in the CNS. Objectives This study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma. Methods HIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care. Results Among the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85–5.80) and 3.59 (2.16–4.50) log10 copies/mL versus 4.79 (3.56–5.25) and 3.80 (2.68–4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients. Conclusions This work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients.

Mutations in TTC19 cause mitochondrial complex III deficiency and neurological impairment in humans and flies

2011 ◽  
Vol 43 (3) ◽  
pp. 259-263 ◽  
Author(s):  
Daniele Ghezzi ◽  
Paola Arzuffi ◽  
Mauro Zordan ◽  
Caterina Da Re ◽  
Costanza Lamperti ◽  
...  
Keyword(s):  
Neurological Impairment ◽  
Complex Iii ◽  
Mitochondrial Complex

Nitric oxide interacts with mitochondrial complex III producing antimycin-like effects

2015 ◽  
Vol 89 ◽  
pp. 602-613 ◽  
Author(s):  
Darío E. Iglesias ◽  
Silvina S. Bombicino ◽  
Laura B. Valdez ◽  
Alberto Boveris
Keyword(s):  
Nitric Oxide ◽  
Complex Iii ◽  
Mitochondrial Complex

Discovery of 1,2,4-triazole-1,3-disulfonamides as dual inhibitors of mitochondrial complex II and complex III

2015 ◽  
Vol 39 (9) ◽  
pp. 7281-7292 ◽  
Author(s):  
Hua Cheng ◽  
Yan-Qing Shen ◽  
Xia-Yan Pan ◽  
Yi-Ping Hou ◽  
Qiong-You Wu ◽  
...  
Keyword(s):  
Complex Iii ◽  
Dual Function ◽  
Mitochondrial Complex ◽  
Complex Ii ◽  
Dual Inhibitors

1,2,4-Triazole-1,3-disulfonamide derivatives as dual function inhibitors of mitochondrial complex II (SQR) and complex III (cyt bc1) were discovered.

scholarly journals Propamidine decreas mitochondrial complex III activity of Botrytis cinerea

BMB Reports ◽  
2010 ◽  
Vol 43 (9) ◽  
pp. 614-621 ◽  
Author(s):  
Fangli Wu ◽  
Weibo Jin ◽  
Juntao Feng ◽  
Anliang Chen ◽  
Zhiqing Ma ◽  
...  
Keyword(s):  
Botrytis Cinerea ◽  
Complex Iii ◽  
Mitochondrial Complex
Sign in / Sign up

Export Citation Format

Share Document